Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

NCT07496463 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07496463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07496463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
July 21, 2026
Completion date
April 30, 2027
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, pseudohypoparathyroidism type 1a